| Name | Title | Contact Details |
|---|
Goldfish Swim School was founded in 2005 by husband and wife team Chris and Jenny McCuiston. Chris and Jenny took a concept that they formulated with nearly two years of research, and cultivated a business that provides results in the learn-to-swim environment that you simply can`t find anywhere else. Their proprietary curriculum and systems were developed after traveling the country in search of the “best practices” to teach babies and young children how to swim. The first school, in Birmingham, Michigan, opened in 2006, and quickly saw success. Opening its doors with over 500 students at inception, Goldfish currently teaches more than 70,000 students per month across the franchise system. At the beginning of 2008, it made sense to begin the franchising process. As of early 2017, we are currently in the process of expanding franchise opportunities throughout the country and internationally, with over 80 schools open or in development in more than 23 states and Canada.
TFS was founded in 1996 and has grown to become a leading global mid-size clinical CRO focusing on small and mid-size life science customers. TFS employs more than 700 professionals throughout 21 countries and currently delivers clinical research services in more than 40 countries.
McDougall Scientific Ltd is a North York, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Fresenius Kabi is a global health care company that specializes in lifesaving medicines and medical technologies for infusion, transfusion and clinical nutrition. Our expansive portfolio of products and global network of science and manufacturing centers provide essential support for the care of critical and chronically ill patients. We are part of Fresenius SE, a health care group with more than 100 years of experience in pharmaceuticals, medical devices and life sciences. Our employees – more than 35,000 worldwide – develop and deliver injectable pharmaceuticals and infusion systems; blood collection, transfusion and cell technologies; and essential nutrients for parenteral nutrition. We have special expertise in medicines for oncology, infection, anesthesia, analgesia and critical care. Our products are used in all sites of care – from hospitals and clinics to blood and plasma centers, and increasingly in patients’ homes. In biosimilars, we are developing products with a focus on oncology and autoimmune diseases.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.